Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for ...

CNW/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the ...

LFTs are a panel of blood tests that help detect liver injury, cholestasis or synthetic dysfunction. Learn what each marker ...

While PBC progresses slowly and many patients do not experience symptoms during the early stages of disease, there are many symptoms to look out for. In later stages of disease, patients may ...

The proportion of male PBC patients in Japan nearly doubled from 12.4% to 20.6% between 2010 and 2021, while the mean age at diagnosis increased by approximately 5 years, suggesting PBC should no ...

Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi (seladelpar) for adults with primary biliary ...

With lifestyle disorders and non-communicable diseases on the rise, many people routinely undergo Liver Function Tests (LFTs) ...

Researchers provide the most comprehensive genetic synopsis of primary biliary cholangitis to date, identifying 44 risk-associated variants with strong evidence for novel genome-wide significant loci.

Liver Awareness Month, observed each October, increases public understanding of the causes, symptoms, and outcomes of liver disease and highlights steps that can be taken at both the individual and ...

Detailed price information for Mirum Pharmaceuticals Inc (MIRM-Q) from The Globe and Mail including charting and trades.

MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.

Scientists and clinician-scientists at the University of Birmingham will lead a major research programme to transform the ...